Melanoma rates in the United States doubled between 1982 and 2011, according to a CDC report.
Scientific Publications
‘Something weird’ may lead to melanoma breakthrough
Western researchers look to take metastatic melanoma survival rates from a gloomy 5 per cent five years after diagnosis to almost 100 per cent, by simply looking where others haven’t.
Possible Link Between Pembrolizumab Cutaneous Adverse Reaction, Progression-Free Survival
Development of cutaneous adverse events while receiving pembrolizumab has been linked with better treatment response, especially in patients with melanoma, suggested a study published online in JAMA Dermatology.
Scientific Journals for July 2015
The Lancet Oncology Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of…
Read More